Blueprint Medicines (NASDAQ:BPMC) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

BPMC has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Canaccord Genuity reissued a “buy” rating and issued a $56.00 price objective on shares of Blueprint Medicines in a research report on Monday, September 11th. Wedbush reissued an “outperform” rating and issued a $82.00 price objective (up previously from $70.00) on shares of Blueprint Medicines in a research report on Monday, November 6th. DA Davidson started coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective for the company. Finally, BidaskClub lowered shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. Two research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $70.47.

Shares of Blueprint Medicines (NASDAQ:BPMC) traded down $2.24 during midday trading on Friday, hitting $72.82. 369,279 shares of the company’s stock traded hands, compared to its average volume of 345,281. Blueprint Medicines has a 12 month low of $25.08 and a 12 month high of $77.91. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same period last year, the company earned ($0.62) EPS. equities analysts predict that Blueprint Medicines will post -3.76 EPS for the current fiscal year.

In related news, insider Kate Haviland sold 6,356 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $60.03, for a total transaction of $381,550.68. Following the completion of the transaction, the insider now owns 6,356 shares of the company’s stock, valued at $381,550.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Lynch sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now directly owns 209,342 shares of the company’s stock, valued at approximately $12,560,520. The disclosure for this sale can be found here. Insiders have sold 72,639 shares of company stock valued at $4,871,743 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Rockefeller Financial Services Inc. purchased a new stake in Blueprint Medicines during the third quarter worth approximately $160,000. Turner Investments LLC purchased a new stake in Blueprint Medicines during the third quarter worth approximately $209,000. Great West Life Assurance Co. Can grew its stake in Blueprint Medicines by 53.6% during the third quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock worth $228,000 after buying an additional 1,163 shares during the period. Ameritas Investment Partners Inc. grew its stake in Blueprint Medicines by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,391 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Blueprint Medicines during the third quarter worth approximately $244,000. 91.40% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/03/blueprint-medicines-bpmc-stock-rating-lowered-by-valuengine.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.